Immune checkpoint inhibitors (ICIs) targeting CTLA4 and PD1 constitute a promising class of
cancer treatment but are associated with several immune-related disorders. We here review …

Objective To define the clinical characteristics, management, and outcome of neurologic
immune-related adverse events (n-irAEs) of immune checkpoint inhibitors (ICIs). Methods …

The delivery of drugs, antigens, and imaging agents benefits from using nanotechnology-
based carriers. The successful translation of nanoformulations to the clinic involves thorough …

Leptomeningeal disease has become increasingly prevalent as novel therapeutic
interventions extend the survival of cancer patients. Although a majority of leptomeningeal …

Abstract Purpose of Review This review highlights the spectrum of neurologic adverse
events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the …

Therapy for advanced melanoma has deeply changed in the last decade with the
introduction of checkpoint and BRAF/MEK inhibitors. Granulomatous reactions have been …

Background After the emergence of new MRI techniques such as susceptibility-and diffusion-
weighted imaging (SWI and DWI) and because of specific imaging characteristics of …

Background: Leptomeningeal carcinomatosis (LC) is the metastatic infiltration of
leptomeninges by malignant cells originating from an extrameningeal primary tumor site …

Immune checkpoint inhibitors such as antibodies to cytotoxic lymphocyte-associated protein
4 (ipilimumab) and programmed cell-death 1 (pembrolizumab, nivolumab) molecules have …

The treatment of cancers of the head and neck, by the virtue of their proximity to and
tendency to arise from and involve anatomic structures vital for deglutition, speech, and …